US5559083A - Composition comprising an isothiazolone compound - Google Patents

Composition comprising an isothiazolone compound Download PDF

Info

Publication number
US5559083A
US5559083A US08/415,517 US41551795A US5559083A US 5559083 A US5559083 A US 5559083A US 41551795 A US41551795 A US 41551795A US 5559083 A US5559083 A US 5559083A
Authority
US
United States
Prior art keywords
composition
isothiazolone compound
cyclodextrine
optionally substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US08/415,517
Inventor
Naoki Kubota
Taiki Kusaka
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Enviro Chemicals Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Assigned to TAKEDA CHEMICAL INDUSTRIES, LTD. reassignment TAKEDA CHEMICAL INDUSTRIES, LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: KUBOTA, NAOKI, KUSAKA, TAIKI
Application granted granted Critical
Publication of US5559083A publication Critical patent/US5559083A/en
Assigned to JAPAN ENVIROCHEMICALS, LTD. reassignment JAPAN ENVIROCHEMICALS, LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: TAKEDA CHEMICAL INDUSTRIES, LTD.
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2

Definitions

  • the present invention relates to a composition
  • a composition comprising an isothiazolone compound mixed with a branched cyclodextrine, which is stable to water.
  • isothiazolone compounds have been given attention as industrial biocides for the purpose of preventing microbe from generating or removing it, and being found that they have a wide range of application and excellent effects.
  • aqueous solution preparations containing an isothiazolone compound which are stable as products for a long period are required.
  • M is a metal selected from among magnesium, calcium, potassium, copper, iron, zinc, manganese, silver, cobalt, nickel and so on
  • X is an anion selected from among chloride, bromide, iodide, sulfate, nitrate, nitrite, acetate, perchlorate, bisulfate, bicarbonate, oxalate, carbonate, phosphate and so on
  • n is an integer to be fitted for the valence of anion and cation
  • metal salt containing metal ions such as calcium and magnesium is not desirable since it causes the occurrence of turbidity or precipitate in the subject.
  • metal stabilizers make the anionic macromolecular disperse system unstable, resulting in the occurrence of cohesion, a fatal problem, so that the aqueous solution preparations disclosed in the above publications are not sufficiently desirable as products.
  • conventional metal salt besides the above does not have a stabilization effect sufficient as a stabilizer or have the same defect as magnesium salt and so on, so that it also cannot provide a desirable product.
  • alkali salt of iodic acid or that of bromic acid were proposed in Japanese Patent Laid-Open Publication No. 286815/93, but it is very difficult to use these stabilizers, since these belong to class 1 dangerous goods and have a danger of explosion.
  • a composition whose skin stimulativity andmucous membrane stimulativity were remarkably reduced by making a clathrate compound with addition of ⁇ , ⁇ and ⁇ cyclodextrine was proposed in Japanese Patent Laid-Open Publication No. 247011/93, but it has been used only as a dust or suspension.
  • the present inventors had earnestly studied and found that it is possible to stabilize an isothiazolone compound to water by mixing a branched cyclodextrine, completing the present invention. That is, the present invention relates to a composition comprising an isothiazolone compound mixed with a branched cyclodextrine, which is stable to water, and to providing an aqueous preparation comprising an isothiazolone compound which is excellent in storage stability and aqueous solution stability.
  • compositions comprising an isothiazolone compound in the present invention show stable effects for a long period of time, and can be used as slime controllers, biocides and biocidal cleaning agents in paper manufacturing pulp factories and a process of cooling water circulation, or industrial biocides such as antiseptics of metal processing oil, textile oils, casein, starch, coating color, paint, emulsion, latex and sizings.
  • An isothiazolone compound in the present invention is represented by the following formula (1) ##STR1## wherein Y is a hydrogen atom or an optionally substituted hydrocarbon group, and X 1 and X 2 are each independently, a hydrogen atom, a halogen atom, a lower alkyl or X 1 and X 2 taken together to form a benzene ring which may be optionally substituted.
  • Y is a hydrogen atom or an optionally substituted hydrocarbon group.
  • a hydrocarbon group represented by Y alkyl, alkenyl, alkynyl, cycloalkyl, aryl, etc., preferably alkyl and cycloalkyl, etc., more preferably alkyl, etc., are exemplified.
  • alkyl represented by Y alkyl having 1 to 10 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, isooctyl, sec-octyl, tert-octyl, nonyl and decyl, preferably alkyl having 1 to 3 carbon atoms such as methyl and ethyl, and alkyl having 7 to 9 carbon atoms such as octyl and tert-octyl, more preferably alkyl having 1 to 3 carbon atoms such as methyl and ethyl, are exemplified.
  • alkenyl represented by Y alkenyl having 2 to 6 carbon atoms such as vinyl, allyl, isopropenyl.
  • alkynyl represented by Y alkynyl having 2 to 6 carbon atoms such as ethynyl, 1-propynyl, 2-propynyl, butynyl and pentynyl, preferably alkynyl having 2 to 4 carbon atoms such as ethynyl and propynyl, are exemplified.
  • cycloalkyl represented by Y cycloalkyl having 3 to 10 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, preferably cycloalkyl having 5 to 7 carbon atoms such as cyclopentyl and cyclohexyl, are exemplified.
  • aryl represented by Y aryl having 6 to 14 carbon atoms such as phenyl, naphthyl, anthryl and phenanthryl, preferably aryl having 6 to 10 carbon atoms such as phenyl, are exemplified.
  • substituents of an optionally substituted hydrocarbon group represented by Y hydroxyl, a halogen atom (e.g. chlorine, fluorine, bromine and iodine), cyano, amino, carboxyl, alkoxy (e.g. alkoxy having 1 to 4 carbon atoms such as methoxy and ethoxy), aryloxy (e.g. C 6-10 aryloxy such as phenoxy), alkylthio (e.g. alkylthio having 1 to 4 carbon atoms such as methylthio and ethylthio) and arylthio (e.g.
  • a halogen atom e.g. chlorine, fluorine, bromine and iodine
  • cyano amino, carboxyl, alkoxy (e.g. alkoxy having 1 to 4 carbon atoms such as methoxy and ethoxy), aryloxy (e.g. C 6-10 aryloxy such as phenoxy), alkylthio
  • C 6-10 arylthio such as phenylthio
  • a halogen atom C 1-4 alkoxy, etc.
  • the hydrocarbon group may be optionally substituted by one to five, preferably one to three, of these substituents, which may be either identical to or different from each other.
  • examples of Y are preferably methyl, octyl and so on, more preferably methyl and so on.
  • X 1 and X 2 are each independently, a hydrogen atom, a halogen atom, a lower alkyl or X 1 and X 2 taken together to form a benzene ring which may be optionally substituted.
  • halogen atom represented by X 1 and X 2 fluorine, chlorine, bromine, iodine and so on, preferably chlorine, etc., are exemplified.
  • alkyl represented by X 1 and X 2 alkyl having 1 to 6 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and pentyl, preferably alkyl having 1 to 4 carbon atoms such as methyl, ethyl and propyl, are exemplified.
  • examples of X 1 are preferably a hydrogen atom or chlorine, etc., more preferably chlorine, etc.
  • examples of X 2 are preferably a hydrogen atom or chlorine, etc., more preferably a hydrogen atom, etc.
  • substituents of a benzene ring hydroxyl, a halogen atom (e.g. chlorine, fluorine, bromine and iodine), cyano, amino, carboxyl, alkyl (e.g. alkyl having 1 to 4 carbon atoms such as methyl, ethyl and propyl), alkoxy (e.g. alkoxy having 1 to 4 carbon atoms such as methoxy and ethoxy) and so on, preferably a halogen atom, C 1-4 alkyl, etc., are exemplified.
  • the benzene ring may be optionally substituted by one to four, preferably one to two, of these substituents, which may be either identical to or different from each other.
  • isothiazolone compound (1) 5-chloro-2-methyl-4-isothiazoline-3-one, 2-methyl-4-isothiazoline-3-one, 2-n-octyl-4-isothiazoline-3-one, 4,5-dichloro-2-n-octyl-4-isothiazoline-3-one, 2-ethyl-4-isothiazoline-3-one, 4,5-dichloro-2-cyclohexyl-4-isothiazoline-3-one, 5-chloro-2-ethyl-4-isothiazoline-3-one, 5-chloro-2-t-octyl-4-isothiazoline-3-one, 1,2-benzisothiazoline-3-one and so on, preferably 5-chloro-2-methyl-4-isothiazoline-3-one, 2-methyl-4-isothiazoline-3-one, 2-n-octyl-4-isothiazoline-3-one, 4,5-dichloro-2-n-n-n-
  • a cyclodextrine ring with an attached monosaccharide or disaccharide branch such as glucose or maltose that is, glucosylcyclodextrine such as G1- ⁇ -cyclodextrine and G1- ⁇ -cyclodextrine, which is a cyclodextrine ring with an attached glucose
  • maltosylcyclodextrine such as G2- ⁇ -cyclodextrine, G2- ⁇ -cyclodextrine and G2- ⁇ -cyclodextrine
  • G2- ⁇ -cyclodextrine ring with an attached maltose G1-G1-, G1-G2-, or G2-G2-maltotoriosylcyclodextrine
  • a cyclodextrine ring with an attached maltotoriose such as G3- ⁇ -cyclodextrine, G3- ⁇ -cyclodextrine and G3- ⁇ -cyclodextrine
  • a composition comprising an isothiazolone compound in the present invention is a solution, and contains water. From the viewpoint of the solubility of an isothiazolone compound, it may further contain an organic solvent.
  • organic solvent alcoholic solvents such as methyl alcohol, ethyl alcohol, propyl alcohol, isopropyl alcohol and butyl alcohol, ketone solvents such as acetone, methyl ethyl ketone and methyl isobutyl ketone, hydrocarbon halide solvents such as dichloroethane, chloroform and carbon tetrachloride, ether solvents such as dioxane and tetrahydrofuran, polar solvents such as dimethylformamide, dimethylsulfoxide and acetonitrile, and glycol solvents such as ethylene glycol, diethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, tripropylene glycol, polypropylene glycol, 1,4-
  • glycol solvents especially ethylene glycol, diethylene glycol, propylene glycol, dipropylene glycol, ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, diethylene glycol monomethyl ether and diethylene glycol monoethyl ether, are exemplified.
  • a composition comprising an isothiazolone compound in the present invention consists of 0.1-10 wt % of isothiazolone compound mixed with 0.1-99.1 wt % of a branched cyclodextrine.
  • water is added in the range of 1-100 wt % to the composition comprising an isothiazolone compound of 10 wt %.
  • an organic solvent is added in the range of 1-100 wt % to the composition comprising an isothiazolone compound of 10 wt %.
  • the proportion of a branched cyclodextrine depends on preparation, but in the case of an aqueous preparation having a high water content, for example, it is better to increase the proportion of a branched cyclodextrine.
  • an isothiazolone compound is made by stirring and mixing every component of the prescribed quantity using industrial original bodies on the market such as Kathon WT, Kathon LX plus (produced by Rohm and Haas Company), Zonen C and Zonen F (produced by Ichikawa Gohsei Chemical Company, Ltd.) with a stirrer until it becomes completely uniformity.
  • an isothiazolone compound and a branched cyclodextrine are prepared to be finally 0.1-40 wt %, preferably 1-20 wt %, and 0.1-60 wt %, preferably 5-40 wt %, respectively.
  • additives whose purpose, usage and so on have been well-known, such as surfactants and oxidation inhibitors, can be added.
  • surfactants well-known surfactants such as soaps, nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants and high molecular surfactants can be used. Among them, nonionic surfactants and anionic surfactants are preferably used.
  • nonionic surfactants polyoxyalkylene aryl phenyl ether, polyoxyethylene nonyl phenyl ether, ethylene oxide-propylene oxide block-copolymer and so on are exemplified.
  • alkylbenzene sulfonic acid metal salt alkylnaphthalene sulfonic acid metal salt
  • polycarboxylic acid surfactants dialkyl sulfosuccinic ester metal salt, polyoxyethylene distyrenyl phenyl ether sulfate ammonium salt, lignin sulfonic acid metal salt, etc.
  • metal salt sodium salt, potassium salt, magnesium salt, etc.
  • phenol oxidation inhibitors such as 2,6-di-t-butyl-4-methylphenol and 2,2'-methylenebis [4-methyl-6-t-butylphenol]
  • amine oxidation inhibitors such as alkyldiphenylamine and N,N'-di-s-butyl-p-phenylenediamine and so on, are exemplified.
  • composition is a solution
  • these surfactants and oxidation inhibitors are added in the ratio of 0.1-5 wt % to a solution of 100 wt %.
  • Zonen F an industrial original body containing ca, 10 wt % of 5-chloro-2-methyl-4-isothiazoline-3-one produced by Ichikawa Gohsei Chemical Company, Ltd.
  • Kathon LX Plus Concentrate an industrial original body containing 5-chloro-2-methyl-4-isothiazoline-3-one of about 18 wt % produced by Rohm and Haas Company
  • a branched cyclodextrine (30% of an aqueous solution: Isoeleat L, produced by Nikken Chemical Ltd., containing 50 wt % or more of maltosylcyclodextrine): a branched CD, and
  • ethylene glycol EG.
  • Example 2-8 Each solution in Examples 2-8 was obtained by mixing and regulating every material to result in the composition (wt %) shown in Table 1 in the same manner as that in Example 1.
  • One hundred grams of a solution was obtained by dissolving 30 g of Zonen F in 50 g of EG and adding 20 g of water thereto.
  • One hundred grams of a solution was obtained by mixing 20 g of Kathon LX Plus Concentrate with 51 g of water, and further adding 29 g of Isoeleat L (20 g of a branched CD and 9 g of water) thereto to be dissolved.
  • Example 10 having the composition shown below in Table 5 was obtained in the same manner as that in Example 9.
  • One hundred grams of a solution was obtained by dissolving 20 g of Kathon LX Plus Concentrate in 80 g of water.
  • One hundred grams of a solution was obtained by previously mixing 15 g of Kathon LX Plus Concentrate, 29 g of Isoeleat L (20 g of a branched CD and 9 g of water) and 11 g of water, while previously mixing 5 g of 1,2-benzisothiazoline-3-one (BIT) with 40 g of dipropylene glycol, and then mixing both of them.
  • Kathon LX Plus Concentrate 29 g of Isoeleat L (20 g of a branched CD and 9 g of water) and 11 g of water
  • BIT 1,2-benzisothiazoline-3-one
  • One hundred grams of a solution was obtained by previously mixing 15 g of Kathon LX Plus Concentrate with 20 g of water, while previously mixing 5 g of 1,2-benzisothiazoline-3-one (BIT) with 60 g of dipropylene glycol, and then mixing both of them.
  • BIT 1,2-benzisothiazoline-3-one
  • Example 11 and Comparative Example 9 were enclosed in glass containers and put in 60° C. of the thermostat, and 7 days later, their residual rates of C1-MIT and BIT (wt %) were measured by high-pressure liquid chromatography.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

A composition comprising an isothiazolone compound mixed with a branched cyclodextrine, wherein the isothiazolone compound can be stabilized to water, so that it is possible to provide an aqueous solution comprising an isothiazolone compound which is excellent in storage stability and aqueous solution stability.

Description

BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a composition comprising an isothiazolone compound mixed with a branched cyclodextrine, which is stable to water.
2. Description of the Prior Art
With increasing demand for industrial water, use of recycle water system has been extensively carried on, but in such use, restraint and control of proliferation of microbe are becoming important problems. And with diversification of industrial materials besides such industrial water, damage caused by proliferation of microbe and that by growth of mold cover a wide range. Especially, it is of urgent necessity to deal with a slime problem of fungi, bacteria, yeasts, algae, etc. which are parasitic on drainage used in a process of paper manufacturing, industrial cooling water, lubricating oil for metal processing, aqueous emulsion, or paper, timber, plywood, paste, pulp, fiber, etc., or microbe damage and so on.
Recently, isothiazolone compounds have been given attention as industrial biocides for the purpose of preventing microbe from generating or removing it, and being found that they have a wide range of application and excellent effects.
Generally speaking, it is desirable for industrial biocides of this kind to be solutions, but it has been known that these isothiazolone compounds are easily decomposed by reducing nucleophilic bodies and so on. Therefore, they are very unstable and have remarkable quality changes for aqueous solution preparations, while an increased proportion of an organic solvent in the solution component brings about, for example, a problem on storage with regard to the Fire Service Act, leading to the difficulty in providing stable products as solutions.
Then, aqueous solution preparations containing an isothiazolone compound which are stable as products for a long period are required. For example, in Japanese Patent Laid-Open Publication Nos. 78102/84, 78103/84, 78104/84, 78109/84, 35603/88 and 50322/88, it was proposed to stabilize an isothiazolone compound in an aqueous solution with metal salt (MXn: M is a metal selected from among magnesium, calcium, potassium, copper, iron, zinc, manganese, silver, cobalt, nickel and so on, X is an anion selected from among chloride, bromide, iodide, sulfate, nitrate, nitrite, acetate, perchlorate, bisulfate, bicarbonate, oxalate, carbonate, phosphate and so on, n is an integer to be fitted for the valence of anion and cation) in order to stabilize an aqueous solution preparation. However, metal salt containing metal ions such as calcium and magnesium is not desirable since it causes the occurrence of turbidity or precipitate in the subject. Especially in the case that it is added to anionic macromolecular disperse system, co-existing metal stabilizers make the anionic macromolecular disperse system unstable, resulting in the occurrence of cohesion, a fatal problem, so that the aqueous solution preparations disclosed in the above publications are not sufficiently desirable as products. And conventional metal salt besides the above does not have a stabilization effect sufficient as a stabilizer or have the same defect as magnesium salt and so on, so that it also cannot provide a desirable product. Besides, alkali salt of iodic acid or that of bromic acid were proposed in Japanese Patent Laid-Open Publication No. 286815/93, but it is very difficult to use these stabilizers, since these belong to class 1 dangerous goods and have a danger of explosion. A composition whose skin stimulativity andmucous membrane stimulativity were remarkably reduced by making a clathrate compound with addition of α, β and γ cyclodextrine was proposed in Japanese Patent Laid-Open Publication No. 247011/93, but it has been used only as a dust or suspension.
SUMMARY OF THE INVENTION
In order to solve these problems, the present inventors had earnestly studied and found that it is possible to stabilize an isothiazolone compound to water by mixing a branched cyclodextrine, completing the present invention. That is, the present invention relates to a composition comprising an isothiazolone compound mixed with a branched cyclodextrine, which is stable to water, and to providing an aqueous preparation comprising an isothiazolone compound which is excellent in storage stability and aqueous solution stability.
The compositions comprising an isothiazolone compound in the present invention show stable effects for a long period of time, and can be used as slime controllers, biocides and biocidal cleaning agents in paper manufacturing pulp factories and a process of cooling water circulation, or industrial biocides such as antiseptics of metal processing oil, textile oils, casein, starch, coating color, paint, emulsion, latex and sizings.
DETAILED DESCRIPTION OF THE INVENTION
An isothiazolone compound in the present invention is represented by the following formula (1) ##STR1## wherein Y is a hydrogen atom or an optionally substituted hydrocarbon group, and X1 and X2 are each independently, a hydrogen atom, a halogen atom, a lower alkyl or X1 and X2 taken together to form a benzene ring which may be optionally substituted.
In the isothiazolone compound represented by the above formula (1), Y is a hydrogen atom or an optionally substituted hydrocarbon group. As a hydrocarbon group represented by Y, alkyl, alkenyl, alkynyl, cycloalkyl, aryl, etc., preferably alkyl and cycloalkyl, etc., more preferably alkyl, etc., are exemplified.
As alkyl represented by Y, alkyl having 1 to 10 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl, pentyl, hexyl, heptyl, octyl, isooctyl, sec-octyl, tert-octyl, nonyl and decyl, preferably alkyl having 1 to 3 carbon atoms such as methyl and ethyl, and alkyl having 7 to 9 carbon atoms such as octyl and tert-octyl, more preferably alkyl having 1 to 3 carbon atoms such as methyl and ethyl, are exemplified.
As alkenyl represented by Y, alkenyl having 2 to 6 carbon atoms such as vinyl, allyl, isopropenyl. 1-propenyl, 2-propenyl and 2-methyl-1-propenyl, preferably alkenyl having 2 to 4 carbon atoms such as vinyl and allyl, are exemplified.
As alkynyl represented by Y, alkynyl having 2 to 6 carbon atoms such as ethynyl, 1-propynyl, 2-propynyl, butynyl and pentynyl, preferably alkynyl having 2 to 4 carbon atoms such as ethynyl and propynyl, are exemplified.
As cycloalkyl represented by Y, cycloalkyl having 3 to 10 carbon atoms such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl, preferably cycloalkyl having 5 to 7 carbon atoms such as cyclopentyl and cyclohexyl, are exemplified.
As aryl represented by Y, aryl having 6 to 14 carbon atoms such as phenyl, naphthyl, anthryl and phenanthryl, preferably aryl having 6 to 10 carbon atoms such as phenyl, are exemplified.
As substituents of an optionally substituted hydrocarbon group represented by Y, hydroxyl, a halogen atom (e.g. chlorine, fluorine, bromine and iodine), cyano, amino, carboxyl, alkoxy (e.g. alkoxy having 1 to 4 carbon atoms such as methoxy and ethoxy), aryloxy (e.g. C6-10 aryloxy such as phenoxy), alkylthio (e.g. alkylthio having 1 to 4 carbon atoms such as methylthio and ethylthio) and arylthio (e.g. C6-10 arylthio such as phenylthio), preferably a halogen atom, C1-4 alkoxy, etc., are exemplified. The hydrocarbon group may be optionally substituted by one to five, preferably one to three, of these substituents, which may be either identical to or different from each other. And examples of Y are preferably methyl, octyl and so on, more preferably methyl and so on.
In an isothiazolone compound represented by the above formula (1), X1 and X2 are each independently, a hydrogen atom, a halogen atom, a lower alkyl or X1 and X2 taken together to form a benzene ring which may be optionally substituted.
As a halogen atom represented by X1 and X2, fluorine, chlorine, bromine, iodine and so on, preferably chlorine, etc., are exemplified.
As alkyl represented by X1 and X2, alkyl having 1 to 6 carbon atoms such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl and pentyl, preferably alkyl having 1 to 4 carbon atoms such as methyl, ethyl and propyl, are exemplified. And examples of X1 are preferably a hydrogen atom or chlorine, etc., more preferably chlorine, etc., and examples of X2 are preferably a hydrogen atom or chlorine, etc., more preferably a hydrogen atom, etc.
As substituents of a benzene ring, hydroxyl, a halogen atom (e.g. chlorine, fluorine, bromine and iodine), cyano, amino, carboxyl, alkyl (e.g. alkyl having 1 to 4 carbon atoms such as methyl, ethyl and propyl), alkoxy (e.g. alkoxy having 1 to 4 carbon atoms such as methoxy and ethoxy) and so on, preferably a halogen atom, C1-4 alkyl, etc., are exemplified. The benzene ring may be optionally substituted by one to four, preferably one to two, of these substituents, which may be either identical to or different from each other.
As examples of the isothiazolone compound (1), 5-chloro-2-methyl-4-isothiazoline-3-one, 2-methyl-4-isothiazoline-3-one, 2-n-octyl-4-isothiazoline-3-one, 4,5-dichloro-2-n-octyl-4-isothiazoline-3-one, 2-ethyl-4-isothiazoline-3-one, 4,5-dichloro-2-cyclohexyl-4-isothiazoline-3-one, 5-chloro-2-ethyl-4-isothiazoline-3-one, 5-chloro-2-t-octyl-4-isothiazoline-3-one, 1,2-benzisothiazoline-3-one and so on, preferably 5-chloro-2-methyl-4-isothiazoline-3-one, 2-methyl-4-isothiazoline-3-one, 2-n-octyl-4-isothiazoline-3-one, 4,5-dichloro-2-n-octyl-4-isothiazoline-3-one, 1,2-benzisothiazoline-3-one, etc., more preferably 5-chloro-2-methyl-4-isothiazoline-3-one, 2-n-octyl-4-isothiazoline-3-one, 4,5-dichloro-2-n-octyl-4-isothiazoline-3-one, 1,2-benzisothiazoline-3-one, etc. are exemplified. These compounds can be properly mixed to be used.
These isothiazolone compounds can be produced by the methods described in U.S. Pat. Nos. 3,761,488, 3,849,430, 3,870,795, 4,067,878, 4,150,026, 4,241,214, 3,517,022, 3,065,123, 3,761,489, 3,849,430, etc. or their equivalents.
As a branched cyclodextrine used in the present invention, a cyclodextrine ring with an attached monosaccharide or disaccharide branch such as glucose or maltose, that is, glucosylcyclodextrine such as G1-β-cyclodextrine and G1-γ-cyclodextrine, which is a cyclodextrine ring with an attached glucose, maltosylcyclodextrine such as G2-α-cyclodextrine, G2-β-cyclodextrine and G2-γ-cyclodextrine, which is a cyclodextrine ring with an attached maltose, G1-G1-, G1-G2-, or G2-G2-maltotoriosylcyclodextrine, which is a cyclodextrine ring with an attached maltotoriose such as G3-α-cyclodextrine, G3-β-cyclodextrine and G3-γ-cyclodextrine, wherein a maltotriosyl is attached to a cyclodextrine ring at the 2- or higher positions, and so on, are cited. Preferably glycosylcyclodextrine and maltosylcyclodextrine are exemplified.
It is desired that a composition comprising an isothiazolone compound in the present invention is a solution, and contains water. From the viewpoint of the solubility of an isothiazolone compound, it may further contain an organic solvent. As the organic solvent, alcoholic solvents such as methyl alcohol, ethyl alcohol, propyl alcohol, isopropyl alcohol and butyl alcohol, ketone solvents such as acetone, methyl ethyl ketone and methyl isobutyl ketone, hydrocarbon halide solvents such as dichloroethane, chloroform and carbon tetrachloride, ether solvents such as dioxane and tetrahydrofuran, polar solvents such as dimethylformamide, dimethylsulfoxide and acetonitrile, and glycol solvents such as ethylene glycol, diethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, tripropylene glycol, polypropylene glycol, 1,4-butanediol, 1,5-pentanediol, ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether and tripropylene glycol monomethyl ether, are exemplified. Preferably glycol solvents, especially ethylene glycol, diethylene glycol, propylene glycol, dipropylene glycol, ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, diethylene glycol monomethyl ether and diethylene glycol monoethyl ether, are exemplified.
A composition comprising an isothiazolone compound in the present invention consists of 0.1-10 wt % of isothiazolone compound mixed with 0.1-99.1 wt % of a branched cyclodextrine. In the case of adding water, water is added in the range of 1-100 wt % to the composition comprising an isothiazolone compound of 10 wt %. In the case of further adding an organic solvent, an organic solvent is added in the range of 1-100 wt % to the composition comprising an isothiazolone compound of 10 wt %. The proportion of a branched cyclodextrine depends on preparation, but in the case of an aqueous preparation having a high water content, for example, it is better to increase the proportion of a branched cyclodextrine.
In the preparation of a solution, an isothiazolone compound is made by stirring and mixing every component of the prescribed quantity using industrial original bodies on the market such as Kathon WT, Kathon LX plus (produced by Rohm and Haas Company), Zonen C and Zonen F (produced by Ichikawa Gohsei Chemical Company, Ltd.) with a stirrer until it becomes completely uniformity. Especially, an isothiazolone compound and a branched cyclodextrine are prepared to be finally 0.1-40 wt %, preferably 1-20 wt %, and 0.1-60 wt %, preferably 5-40 wt %, respectively.
Furthermore, in the present invention, additives whose purpose, usage and so on have been well-known, such as surfactants and oxidation inhibitors, can be added.
As the surfactants, well-known surfactants such as soaps, nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants and high molecular surfactants can be used. Among them, nonionic surfactants and anionic surfactants are preferably used.
As the nonionic surfactants, polyoxyalkylene aryl phenyl ether, polyoxyethylene nonyl phenyl ether, ethylene oxide-propylene oxide block-copolymer and so on are exemplified.
As the anionic surfactants, alkylbenzene sulfonic acid metal salt, alkylnaphthalene sulfonic acid metal salt, polycarboxylic acid surfactants, dialkyl sulfosuccinic ester metal salt, polyoxyethylene distyrenyl phenyl ether sulfate ammonium salt, lignin sulfonic acid metal salt, etc. are cited, and as metal salt, sodium salt, potassium salt, magnesium salt, etc. are exemplified.
As the oxidation inhibitors, phenol oxidation inhibitors such as 2,6-di-t-butyl-4-methylphenol and 2,2'-methylenebis [4-methyl-6-t-butylphenol], amine oxidation inhibitors such as alkyldiphenylamine and N,N'-di-s-butyl-p-phenylenediamine and so on, are exemplified.
When the composition is a solution, for example, these surfactants and oxidation inhibitors are added in the ratio of 0.1-5 wt % to a solution of 100 wt %.
DESCRIPTION OF PREFERRED EMBODIMENTS
The present invention is concretely described below with examples and comparative examples, but is not limited to the examples. Here, the terms used in the examples and comparative examples are as follows:
Zonen F (an industrial original body containing ca, 10 wt % of 5-chloro-2-methyl-4-isothiazoline-3-one produced by Ichikawa Gohsei Chemical Company, Ltd.)
Kathon LX Plus Concentrate (an industrial original body containing 5-chloro-2-methyl-4-isothiazoline-3-one of about 18 wt % produced by Rohm and Haas Company)
a branched cyclodextrine (30% of an aqueous solution: Isoeleat L, produced by Nikken Chemical Ltd., containing 50 wt % or more of maltosylcyclodextrine): a branched CD, and
ethylene glycol: EG.
EXAMPLE 1
One hundred grams of a solution was obtained by previously mixing 30 g of Zonen F with 11 g of EG, while previously mixing 29 g of Isoeleat L (a 20 g of branched CD and 9 g of water) with 30 g of water, and then mixing both of them.
EXAMPLES 2-8
Each solution in Examples 2-8 was obtained by mixing and regulating every material to result in the composition (wt %) shown in Table 1 in the same manner as that in Example 1.
              TABLE 1                                                     
______________________________________                                    
Examples   2       3     4     5   6     7   8                            
______________________________________                                    
Zonen F    30      30    30    30  30    30  30                           
Branched CD                                                               
           30      30    30    30  35    35  35                           
Water      10      20    30    40  15    25  35                           
EG         30      20    10    0   20    10  0                            
______________________________________                                    
COMPARATIVE EXAMPLE 1
One hundred grams of a solution was obtained by dissolving 30 g of Zonen F in 50 g of EG and adding 20 g of water thereto.
COMPARATIVE EXAMPLES 2-7
Each solution in Comparative Examples 2-7 was obtained by mixing and regulating every material to result in the composition (wt %) shown in Table 2 in the same manner as that in Comparative Example 1.
              TABLE 2                                                     
______________________________________                                    
Comparative                                                               
Examples     2     3        4   5     6   7                               
______________________________________                                    
Zonen F      30    30       30  30    30  30                              
Water        20    30       40  15    25  35                              
EG           50    40       30  55    45  35                              
______________________________________                                    
EXPERIMENTAL EXAMPLE 1
The solutions according to Examples 1-8 and Comparative Examples 1-7 were enclosed in glass containers and put in of 60° C. of the thermostat, and 7 days later, their residual rates of C1-MIT (wt %) were measured by high-pressure liquid chromatography.
The results are shown in Tables 3 and 4.
              TABLE 3                                                     
______________________________________                                    
Examples 1     2       3   4     5   6     7   8                          
______________________________________                                    
Content  88    97      90  87    84  86    84  86                         
______________________________________                                    
              TABLE 4                                                     
______________________________________                                    
Comparative                                                               
Examples   1       2     3     4   5     6   7                            
______________________________________                                    
Content    0       0     0     0   0     0   0                            
______________________________________                                    
It is proved that the residual rates in the solutions containing a branched cyclodextrine are higher.
EXAMPLE 9
One hundred grams of a solution was obtained by mixing 20 g of Kathon LX Plus Concentrate with 51 g of water, and further adding 29 g of Isoeleat L (20 g of a branched CD and 9 g of water) thereto to be dissolved.
EXAMPLE 10
The solution in the Example 10 having the composition shown below in Table 5 was obtained in the same manner as that in Example 9.
              TABLE 5                                                     
______________________________________                                    
Examples               9     10                                           
______________________________________                                    
Kathon LX Plus Concentrate                                                
                       20    20                                           
Branched CD            20    30                                           
Water                  60    50                                           
______________________________________                                    
COMPARATIVE EXAMPLE 8
One hundred grams of a solution was obtained by dissolving 20 g of Kathon LX Plus Concentrate in 80 g of water.
EXPERIMENTAL EXAMPLE 2
The solutions according to Examples 9 and 10, and Comparative Example 8 were enclosed in glass containers and put in 60° C. of the thermostat, and 7 days later, their residual rates of C1-MIT (wt %) were measured by high-pressure liquid chromatography.
              TABLE 6                                                     
______________________________________                                    
Examples           9     10                                               
______________________________________                                    
Content            81    88                                               
Comparative Example                                                       
                   8                                                      
Content            0                                                      
______________________________________                                    
It is proved that the residual rates in the solutions containing a branched cyclodextrine are higher.
EXAMPLE 11
One hundred grams of a solution was obtained by previously mixing 15 g of Kathon LX Plus Concentrate, 29 g of Isoeleat L (20 g of a branched CD and 9 g of water) and 11 g of water, while previously mixing 5 g of 1,2-benzisothiazoline-3-one (BIT) with 40 g of dipropylene glycol, and then mixing both of them.
COMPARATIVE EXAMPLE 9
One hundred grams of a solution was obtained by previously mixing 15 g of Kathon LX Plus Concentrate with 20 g of water, while previously mixing 5 g of 1,2-benzisothiazoline-3-one (BIT) with 60 g of dipropylene glycol, and then mixing both of them.
EXPERIMENTAL EXAMPLE 3
The solutions according to Example 11 and Comparative Example 9 were enclosed in glass containers and put in 60° C. of the thermostat, and 7 days later, their residual rates of C1-MIT and BIT (wt %) were measured by high-pressure liquid chromatography.
              TABLE 7                                                     
______________________________________                                    
         Example 11                                                       
                 Comparative Example 9                                    
______________________________________                                    
C1-MIT     90        0                                                    
BIT        98        97                                                   
______________________________________                                    
It is proved that the residual rate in the solution containing a branched cyclodextrine is unexceptionally higher.

Claims (12)

What is claimed is:
1. An industrial biocide composition which consists essentially of an isothiazolone compound mixed with a branched cyclodextrin, wherein the isothiazolone compound is represented by the following formula: ##STR2## wherein Y is a hydrogen atom or an optionally substituted hydrocarbon group, and X1 and X2 are each independently a hydrogen atom, a halogen atom, a lower alkyl or X1 and X2 are taken together to form a benzene ring which may be optionally substituted.
2. The composition as claimed in claim 1, which consists essentially of a branched cyclodextrin adduct of the isothiazolone compound.
3. The composition as claimed in claim 1, wherein the branched cyclodextrin is maltosylcyclodextrin.
4. The composition as claimed in claim 1, wherein the hydrocarbon group is (i) C1-10 alkyl, (ii) C2-6 alkenyl, (iii) C2-6 alkynyl, (iv) C3-10 cycloalkyl, or (v) C6-14 aryl, each of which may be optionally substituted by one to five substituents selected from hydroxyl, a halogen atom, cyano, amino, carboxyl, C1-4 alkoxy, C6-10 aryloxy, C1-4 alkylthio and C6-10 arylthio.
5. The composition as claimed in claim 1, wherein the lower alkyl has one to six carbon atoms.
6. The composition as claimed in claim 1, wherein the benzene ring may be optionally substituted by one to four substituents selected from hydroxyl, a halogen atom, cyano, amino, carboxyl, C1-4 alkyl and C1-4 alkoxy.
7. The composition as claimed in claim 1, wherein the isothiazolone compound is 5-chloro-2-methyl-4-isothiazoline-3-one.
8. The composition as claimed in claim 1, which is a solution.
9. The composition as claimed in claim 1, which further contains water.
10. The composition as claimed in claim 1, which further contains an organic solvent.
11. The composition as claimed in claim 10, wherein the organic solvent is a glycol solvent.
12. The composition as claimed in claim 1, wherein the branched cyclodextrin and the isothiazolone compound are premixed.
US08/415,517 1994-04-04 1995-04-03 Composition comprising an isothiazolone compound Expired - Fee Related US5559083A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP6628194 1994-04-04
JP6-066281 1994-04-04

Publications (1)

Publication Number Publication Date
US5559083A true US5559083A (en) 1996-09-24

Family

ID=13311299

Family Applications (1)

Application Number Title Priority Date Filing Date
US08/415,517 Expired - Fee Related US5559083A (en) 1994-04-04 1995-04-03 Composition comprising an isothiazolone compound

Country Status (1)

Country Link
US (1) US5559083A (en)

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0895718A2 (en) * 1997-08-07 1999-02-10 Wacker-Chemie GmbH Composition comprising a complex cyclodextrin with isthiazolinone in a watersoluble coating and its use
EP0923867A1 (en) * 1997-12-22 1999-06-23 Kurita Water Industries Ltd. Antimicrobial composition and their use
US6069142A (en) * 1998-12-23 2000-05-30 Calgon Corporation Synergistic antimicrobial combination of 4,5-dichloro-2-N-octyl-4-isothiazolin-3-one and a mixture of a chlorinated isocyanurate and a bromide compound and methods of using same
EP1088631A1 (en) * 1999-09-30 2001-04-04 Wacker-Chemie GmbH Wood treatment agent, process for its preparation and its use
US6280657B1 (en) * 1998-05-27 2001-08-28 Rohm And Haas Company Ketoxime solutions of biocides
US6403533B2 (en) * 2000-01-27 2002-06-11 Rohm And Haas Company Stabilized microbicide formulation
KR100383098B1 (en) * 2000-05-10 2003-05-12 에스케이케미칼주식회사 A method inhibiting precipitation of isothiazolone solution and a composition the same
KR100385714B1 (en) * 1999-12-31 2003-05-27 에스케이케미칼주식회사 A stabilized isothiazolone composition and method of stabilization of isothiazolone
US20050279350A1 (en) * 1999-07-12 2005-12-22 Capnia Incorporated Methods and apparatus for relieving headaches, rhinitis and other common ailments
US20060076011A1 (en) * 1999-11-08 2006-04-13 Capnia, Incorporated Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
US20060172017A1 (en) * 1999-11-08 2006-08-03 Capnia, Incorporated Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
KR100615571B1 (en) * 1999-12-31 2006-08-25 에스케이케미칼주식회사 Composition treating water for inhibiting growth of microorganism and scale
US20070039615A1 (en) * 1999-11-08 2007-02-22 Capnia, Incorporated Methods and apparatus for treating rhinitis
KR100716127B1 (en) * 2001-07-06 2007-05-10 에스케이케미칼주식회사 Multi-functional one-component type cooling water treatment agent and method for water treatment using the same
KR100740054B1 (en) * 2000-10-13 2007-07-16 에스케이케미칼주식회사 Isothiazolone composition

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5024997A (en) * 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
JPH05247011A (en) * 1992-03-04 1993-09-24 Permachem Asia Ltd Clathrate compound
US5306725A (en) * 1989-03-01 1994-04-26 Katayama Chemical Inc. Stabilized isothiazolone liquid formulation
US5376509A (en) * 1991-11-27 1994-12-27 Konica Corporation Solid processing compositions for light-sensitive silver halide photographic materials

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5306725A (en) * 1989-03-01 1994-04-26 Katayama Chemical Inc. Stabilized isothiazolone liquid formulation
US5024997A (en) * 1990-06-22 1991-06-18 American Home Products Corporation Palatable ibuprofen solutions
US5376509A (en) * 1991-11-27 1994-12-27 Konica Corporation Solid processing compositions for light-sensitive silver halide photographic materials
JPH05247011A (en) * 1992-03-04 1993-09-24 Permachem Asia Ltd Clathrate compound

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0895718A3 (en) * 1997-08-07 1999-06-16 Wacker-Chemie GmbH Composition comprising a complex cyclodextrin with isthiazolinone in a watersoluble coating and its use
EP0895718A2 (en) * 1997-08-07 1999-02-10 Wacker-Chemie GmbH Composition comprising a complex cyclodextrin with isthiazolinone in a watersoluble coating and its use
EP0923867A1 (en) * 1997-12-22 1999-06-23 Kurita Water Industries Ltd. Antimicrobial composition and their use
US6159999A (en) * 1997-12-22 2000-12-12 Kurita Water Industries Ltd. Antimicrobial and antiseptic methods using antimicrobial composition
SG82593A1 (en) * 1997-12-22 2001-08-21 Kurita Water Ind Ltd Antimicrobial composition and their use
US6280657B1 (en) * 1998-05-27 2001-08-28 Rohm And Haas Company Ketoxime solutions of biocides
US6069142A (en) * 1998-12-23 2000-05-30 Calgon Corporation Synergistic antimicrobial combination of 4,5-dichloro-2-N-octyl-4-isothiazolin-3-one and a mixture of a chlorinated isocyanurate and a bromide compound and methods of using same
US20060237003A1 (en) * 1999-07-12 2006-10-26 Capnia, Incorporated Methods for treating headaches
US20070017508A1 (en) * 1999-07-12 2007-01-25 Capnia, Incorporated Methods for treating jaw pain
US20060243276A1 (en) * 1999-07-12 2006-11-02 Capnia, Incorporated Methods for treating rhinitis and conjunctivitis
US20060237004A1 (en) * 1999-07-12 2006-10-26 Capnia, Incorporated Methods for treating trigeminal neuralgia
US20050279350A1 (en) * 1999-07-12 2005-12-22 Capnia Incorporated Methods and apparatus for relieving headaches, rhinitis and other common ailments
EP1088631A1 (en) * 1999-09-30 2001-04-04 Wacker-Chemie GmbH Wood treatment agent, process for its preparation and its use
US20060172017A1 (en) * 1999-11-08 2006-08-03 Capnia, Incorporated Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
US20060076011A1 (en) * 1999-11-08 2006-04-13 Capnia, Incorporated Methods and apparatus for the enhanced delivery of physiologic agents to tissue surfaces
US20070039615A1 (en) * 1999-11-08 2007-02-22 Capnia, Incorporated Methods and apparatus for treating rhinitis
KR100615571B1 (en) * 1999-12-31 2006-08-25 에스케이케미칼주식회사 Composition treating water for inhibiting growth of microorganism and scale
KR100385714B1 (en) * 1999-12-31 2003-05-27 에스케이케미칼주식회사 A stabilized isothiazolone composition and method of stabilization of isothiazolone
US6403533B2 (en) * 2000-01-27 2002-06-11 Rohm And Haas Company Stabilized microbicide formulation
KR100383098B1 (en) * 2000-05-10 2003-05-12 에스케이케미칼주식회사 A method inhibiting precipitation of isothiazolone solution and a composition the same
KR100740054B1 (en) * 2000-10-13 2007-07-16 에스케이케미칼주식회사 Isothiazolone composition
KR100716127B1 (en) * 2001-07-06 2007-05-10 에스케이케미칼주식회사 Multi-functional one-component type cooling water treatment agent and method for water treatment using the same

Similar Documents

Publication Publication Date Title
US5559083A (en) Composition comprising an isothiazolone compound
JP2622114B2 (en) Antimicrobial composition
JP2017019789A (en) Microorganism controlling agent
GB2201595A (en) Microbiological control agent
KR19990036499A (en) Stable bactericidal composition
JPH05286815A (en) Industrial fungicide
JP4245097B2 (en) Harmful microorganism eradication agent
EP0606986B1 (en) Iron stabilizers for 3-isothiazolones
US20050065199A1 (en) Low-salt or salt-free microbicidal composition based on isothiazolone derivatives and pyrion disulphide
JP3576255B2 (en) Isothiazolone-based compound-containing composition
JPH0647524B2 (en) Industrial antibacterial agent
JPH0840810A (en) Industrial antimicrobial agent
JP3943152B2 (en) Composition containing isothiazolone compound and method for stabilizing isothiazolone compound
KR100250787B1 (en) Fungicidal compositions
JP4776108B2 (en) Industrial microbial control agent
KR20020000500A (en) Industrial microbicide
US5919400A (en) Stabilized isothiazolone solution
JPH0641457B2 (en) Stabilized solution of isothiazolone compounds
JP3651950B2 (en) Halocyanoacetamide-containing composition
US20080299225A1 (en) Stable microbicidal composition
US3801332A (en) Organic mercury compositions
US3312588A (en) Method of preserving aqueous organic dispersions from microbial attack
JP4201885B2 (en) Harmful microorganism eradication agent
JP2891623B2 (en) Industrial antibacterial agent
US4962123A (en) Thiocyanato-butenes as inhibitors of microorganism growth

Legal Events

Date Code Title Description
AS Assignment

Owner name: TAKEDA CHEMICAL INDUSTRIES, LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:KUBOTA, NAOKI;KUSAKA, TAIKI;REEL/FRAME:007457/0279

Effective date: 19950330

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: LTOS); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: JAPAN ENVIROCHEMICALS, LTD., JAPAN

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:TAKEDA CHEMICAL INDUSTRIES, LTD.;REEL/FRAME:014852/0840

Effective date: 20031205

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20080924